在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

以色列Protalix Biotherapeutics
Protalix Biotherapeutics 公司是一家以色列的生物技術(shù)公司，以其獨(dú)有的植物細(xì)胞培養(yǎng)技術(shù)和生物反應(yīng)器系統(tǒng)，來(lái)高效表達(dá)人類治療用蛋白。 公司準(zhǔn)備通過(guò)這種技術(shù)平臺(tái)來(lái)大規(guī)模生產(chǎn)蛋白和抗體，為其它制藥和生物技術(shù)公司提供服務(wù)。其主要產(chǎn)品——治療高雪氏癥（ Gaucher's Disease ）的重組蛋白——即將進(jìn)入臨床試驗(yàn)。

We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx? protein expression system. Using our ProCellEx? system we are developing a pipeline of proprietary recombinant therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx? protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications.In addition, we believe our ProCellEx protein expression system will enable us to express and produce bio similar or "generic" versions of other recombinant proteins not protected through patents in a cost effective manner. Because we are targeting primarily biologically equivalent versions ("Biosimilar versions") of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other biopharmaceutical development processes for novel therapeutic proteins.